ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-B7-H3/CD28 Bispecific Antibody XmAb808

Also written as “XmAb808” and “XmAb®808”.

Its studies are mostly in Ovarian Neoplasms · Squamous Cell Carcinoma of Head and Neck, led by Xencor.

Furthest: phase 1, since Oct 11, 20222 company-led studies, 1 open or runningNext primary completion: Dec 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Xencor21 open or runningphase 1since Oct 11, 2022Oct 11, 2022Dec 2028phase 1 · NCT07593092

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 11, 2022First study: phase 1 study in Squamous Cell Carcinoma of Head and NeckFirst studyNCT05585034 · 60 enrolled · United States
  2. May 11, 2026Phase 1 study in Ovarian NeoplasmsNCT07593092 · 90 planned · United States

Ahead

  1. Dec 2028Primary completion: phase 1 study in Ovarian NeoplasmsNCT07593092

TargetBeta

CD276 →CD28 →read by rule
“A bispecific antibody directed against the tumor-associated antigen (TAA) and immunoregulatory protein B7-homologue 3 (B7-H3, CD276) and the co-stimulatory T-cell surface glycoprotein CD28, ”NCIt, by rule

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07593092Ovarian Neoplasms · United States1RecruitingDec 202890
NCT05585034Squamous Cell Carcinoma of Head and Neck · United States1CompletedMay 20, 202560

How it is read

Names in the registry

  • “XmAb808”, 1 entry
  • “XmAb®808”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.